49 completed. 49 Phase 2, 9 Phase 1, 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 49 | Completed 49 |
| Phase 1 | 9 | Completed 9 |
| Phase 3 | 8 | Completed 8 |
Follow Malabsorption Syndromes: new trials by email Literature Review of Malabsorption Syndromes trials Research Report on Malabsorption Syndromes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease KAN-101, Placebo - Celiac Disease, Coeliac Disease | Phase 2 | Completed | Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA | 55 | 2023-12-13 | 2025-12-18 |
| Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission Ritlecitinib, Placebo, Gluten - Celiac Disease | Phase 2 | Completed | Massachusetts General Hospital | 62 | 2023-03-01 | 2026-09-15 |
| A Study to Assess the Safety of TPM502 in Adults With Celiac Disease TPM502, Placebo - Celiac Disease | Phase 2 | Completed | Topas Therapeutics GmbH | 28 | 2022-12-12 | 2025-12-03 |
| A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo - Celiac Disease | Phase 2 | Completed | Takeda | 153 | 2022-06-30 | 2025-08-20 |
| Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet Placebo, TAK-101, Gluten - Celiac Disease | Phase 2 | Completed | Takeda | 102 | 2022-06-23 | 2026-10-06 |
| Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC) Apraglutide - Short Bowel Syndrome | Phase 2 | Completed | VectivBio AG | 10 | 2021-06-14 | 2025-06-18 |
| Teriflunomide vs. Placebo During Gluten Challenge in Celiac Disease Teriflunomide Oral Tablet - Celiac Disease | Phase 1 / Phase 2 | Completed | Oslo University Hospital | 15 | 2021-04-16 | 2025-05-16 |
| PRV-015 in Gluten-free Diet Non-responsive Celiac Disease PRV-015, Placebo - Celiac Disease | Phase 2 | Completed | Provention Bio, a Sanofi Company | 388 | 2020-08-24 | 2025-10-20 |
| A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Celiac Disease AGY, placebo - Celiac Disease | Phase 2 | Completed | Igy Inc. | 161 | 2019-10-29 | 2024-03-06 |
| Latiglutenase as a Treatment for Celiac Disease Latiglutenase, Placebo - Celiac Disease | Phase 2 | Completed | Immunogenics, LLC | 79 | 2019-03-01 | 2021-12-15 |
| Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease TIMP-GLIA, Placebo - Celiac Disease | Phase 2 | Completed | Takeda | 34 | 2018-11-11 | 2020-08-12 |
| Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support FE203799 GLP-2 analogue, FE203799 Placebo GLP-2 analogue - Short Bowel Syndrome | Phase 1 / Phase 2 | Completed | GlyPharma Therapeutics | 8 | 2018-05-08 | 2024-10-26 |
| Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal Insufficiency FE203799 - SBS - Short Bowel Syndrome | Phase 1 / Phase 2 | Completed | GlyPharma Therapeutics | 8 | 2018-05-02 | 2024-10-24 |
| Effectiveness of a Micronutrient Supplement to Lower Plasma Homocysteine MDEG2 Pilot Supplementation Trial novel micronutrient, existing micronutrient supplement, UNIMMAP - Micronutrient Deficiencies, Hyperhomocysteinemia | Phase 2 | Completed | London School of Hygiene and Tropical Medicine | 298 | 2018-04-26 | 2019-01-22 |
| Bifidobacterium Infantis NLS Super Strain for Celiac Disease Patients on a Gluten-free Diet With Persistent Gastrointestinal Symptoms Bifidobacterium infantis NLS super strain (Natren LIFE START®2), Placebo - Celiac Disease | Phase 2 | Completed | Global Institute of Probiotics | 18 | 2017-07-21 | 2018-08-24 |
| Use of Pancreatic Enzymes in Short Bowel Syndrome Pancreatic Enzyme - Short Bowel Syndrome | Phase 2 | Completed | Children's Hospital of Philadelphia | 16 | 2017-03-24 | 2020-03-20 |
| A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease AMG 714, Placebo, Placebo Gluten Challenge - Celiac Disease | Phase 2 | Completed | Amgen | 64 | 2016-04-13 | 2019-12-03 |
| A Phase 2 Trial Testing ZP1848 in Patients With SBS ZP1848 - Short Bowel Syndrome | Phase 2 | Completed | Zealand Pharma | 18 | 2016-02-01 | 2017-06-21 |
| Efficacy, Safety, and Tolerability Study of RP-G28 in Subjects With Lactose Intolerance RP-G28, Placebo - Lactose Intolerance | Phase 2 / Phase 3 | Completed | Ritter Pharmaceuticals, Inc. | 377 | 2016-02-01 | 2018-04-04 |
| The Relationship Between HHcy and Contrast-induced Nephropathy in Hypertensive Patients After Coronary Artery Diagnosis and Treatment Enalapril Maleate Tablets(as the program-based antihypertension), Enalapril Maleate and Folic Acid tablets(as the program-based antihypertension), Placebo - Homocysteine, Coronary Disease | Phase 2 / Phase 3 | Completed | Fuling Central Hospital of Chongqing City | 4000 | 2015-11-01 | 2019-08-06 |
Showing 20 of 49. Sign in to see all of them.
Celiac Disease (30) · Short Bowel Syndrome (10) · Cholestasis (3) · Diarrhea (2) · Hyperhomocysteinemia (2) · Irritable Bowel Syndrome (2) · Lactose Intolerance (2) · Steatorrhea (2) · Ancylostomiasis (1) · Coronary Disease (1) · Cystic Fibrosis (1) · Dermatitis Herpetiformis (1) · Enterocolitis, Necrotizing (1) · Exocrine Pancreatic Insufficiency (1)
Digestive System Diseases (47) · Gastrointestinal Diseases (46) · Intestinal Diseases (46) · Metabolic Diseases (39) · Nutritional and Metabolic Diseases (39) · Pathological Conditions, Signs and Symptoms (13) · Pathologic Processes (10) · Postoperative Complications (10) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Genetic Diseases, Inborn (6) · Metabolism, Inborn Errors (5) · Bile Duct Diseases (3) · Biliary Tract Diseases (3) · Carbohydrate Metabolism, Inborn Errors (3)
Glutens (5) · larazotide acetate (5) · ALV003 (3) · fish oil triglycerides (3) · ASP-1 protein, Necator americanus (2) · RP-G28 (2) · AMG-714 (1) · CCX282-B (1) · Colesevelam Hydrochloride (1) · Diet Therapy (1) · Diet, Gluten-Free (1) · Enalapril (1) · Fish Oils (1) · Growth Hormone (1) · Pancrelipase (1)
9 Meters Biopharma, Inc. (5) · Takeda (3) · All India Institute of Medical Sciences (2) · Alvine Pharmaceuticals Inc. (2) · Amgen (2) · GlyPharma Therapeutics (2) · Oslo University Hospital (2) · Ritter Pharmaceuticals, Inc. (2) · Amsterdam UMC, location VUmc (1) · BioLineRx, Ltd. (1) · Children's Hospital of Philadelphia (1) · Emory University (1) · Fuling Central Hospital of Chongqing City (1) · Global Institute of Probiotics (1) · Heim Pal Children's Hospital (1)
United States (22) · Canada (9) · Finland (7) · Australia (4) · Netherlands (4) · Norway (4) · Denmark (3) · France (3) · Spain (3) · Belgium (2) · Germany (2) · India (2) · Italy (2) · Poland (2) · Argentina (1)
Tomasz Masior (3) · A James M Daveson, MBBS (1) · Alberto Lanzini, MD, PhD (1) · Alessio Fasano, MD (1) · Alex Loukas, BSc Hon, PhD (UQ) (1) · Alexander Loukas, PhD (1) · Andrew Clouston, MBBS (Qld) PhD (Qld) FRCPA (1) · Andrew Pascoe, B. Pharm, B.Sc, MBBS, FRACP (1) · Andrew Prentice, PhD (1) · Barbara Zanini, MD, PhD (1) · Dianne Jones, BAppSc (1) · Dianne Jones, RN RM BAppSc (1)
PMID 24583059, PMID 41039829, PMID 19661785, PMID 19829124, PMID 19879973, PMID 20980771, PMID 21408161, PMID 21791335, PMID 22752636, PMID 22825365, PMID 23163616, PMID 23453547, PMID 24124328, PMID 24330605, PMID 24795483, PMID 25683116, PMID 25987795, PMID 26134988, PMID 30880176, PMID 31326433, PMID 31408467, PMID 31494096, PMID 32059815, PMID 33032471, PMID 33038344, PMID 33722583, PMID 34287970, PMID 34287979, PMID 34365905, PMID 34695449, PMID 35622082, PMID 35931103, PMID 39461299, PMID 41903849
2015 (1), R01DK054681 (1), R01DK055850 (1), R33AT009637 (1)